(+)-Irinotecan; CPT-11; VAL-413(free base) MedChemExpress (MCE)

Product Name	Irinotecan
Synonyms	DQ-2805;SN-38-11;Irinotecan;Irinotecan base;Irinotecan(TECANS);Irinotecan Free Base;Irinotecan (free Base)
CAS	97682-44-5
EINECS	691-567-9
Chemical Formula	C33H38N4O6
Molecular Weight	586.68
inchi	InChI=1/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1
Package	10 mM * 1 mL;50 mg;100 mg;200 mg;500 mg
Price	Email to quote
Descriptions	Irinotecan Irinotecan MedChemExpress (MCE) HY-16562 97682-44-5 (+)-Irinotecan Descriptions Irinotecan Irinotecan MedChemExpress (MCE) HY-16562 97682-44-5 (+)-Irinotecan CPT-11 VAL-413(free base) 99.97% 4°C, protect from light In solvent : -80°C, 6 months -20°C, 1 month (protect from light) Room temperature in continental US may vary elsewhere. Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex. Irinotecan is a topoisomerase I inhibitor. Irinotecan inhibits the growth of LoVo and HT-29 cells, with IC50s of 15.8 ± 5.1 and 5.17 ± 1.4 μM, respectively, and induces similar amounts of cleavable complexes in both in LoVo and HT-29 cells[2]. Irinotecan suppresses the proliferation of human umbilical vein endothelial cells (HUVEC), with an IC50 of 1.3 μM[3]. Irinotecan (CPT-11, 5 mg/kg) significantly inhibits the growth of tumors by intratumoral injection daily for 5 days, on two consecutive weeks in rats, and such effects also occur via continuous intraperitoneal infusion by osmotic minipump into mice. However, Irinotecan (10 mg/kg) shows no effect on the growth of tumor by i.p[1]. Irinotecan (CPT-11, 100-300 mg/kg, i.p.) apparently suppresses tumor growth of HT-29 xenografts in athymic female mice by day 21. The two groups of Irinotecan (125 mg/kg) plus TSP-1 (10 mg/kg per day) or Irinotecan (150 mg/kg) in combination TSP-1 (20 mg/kg per day) are nearly equally effective and inhibit tumor growth 84% and 89%, respectively, and both are more effective than Irinotecan alone at doses of 250 and 300 mg/kg[3]. Irinotecan has been administered by intratumoral injection at 0.1 cc volume of the appropriate solution, for a doses of 5 mg/kg daily for 5 days, on two consecutive weeks, followed by a 7-days rest period, referred to as one cycle of therapy. Rats receive three cycles over a period of 8 weeks. Control animals receive 0.1 cc of sterile 0.9% sodium chloride solution by intratumoral injection in the same rule of administration as that of animals of group II[1]. Exponentially growing cells are seeded in 20 cm2 dishes with an optimal cell number for each cell line (20,000 for LoVo cells, 100,000 for HT-29 cells). They are treated 2 days later with increasing concentrations of irinotecan or SN-38 for one cell doubling time (24 h for LoVo cells, 40 h for HT-29 cells). After washing with 0.15 M NaCl, the cells are further grown for two doubling times in normal medium, detached from the support with trypsin-EDTA and counted in a hemocytometer. The IC50 values are then estimated as the drug concentrations responsible for 50% growth inhibition as compared with cells incubated without drug[2]. Topoisomerase I \| \| \| \| \| \| \| \| \| \| [1]. Morales C, et al. Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor. J Neurooncol. 2002 Feb 56(3):219-26. [Content Brief]* [2]. Pavillard V, et al. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol. 2002 Apr 49(4):329-35. Epub 2002 Jan 30. [Content Brief] [3]. Allegrini G, et al. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol. 2004 Mar 53(3):261-6. Epub 2003 Dec 5. [Content Brief] [4]. Dela Cruz FS, et al. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Med. 2016 Oct 31 8(1):116. [Content Brief] [5]. Huang MY, et al. Chemotherapeutic agent CPT-11 eliminates peritoneal resident macrophages by inducing apoptosis. Apoptosis. 2016 Feb 21(2):130-42. [Content Brief]
Supplier Website	http://www.medchemexpress.com/Irinotecan.html
Last Update	2025-10-14 16:03:33

MedChemExpress (MCE) also provides

Thalidomide-4-O-C2-NH2

Category: Signaling Pathways
CAS: 2341840-99-9
Last Update: 2025-10-14 16:03:33

Netupitant N-oxide

Category: Signaling Pathways
CAS: 910808-11-6
Last Update: 2025-10-14 16:03:33

MK-0812

Category: Signaling Pathways
CAS: 624733-88-6
Last Update: 2025-10-14 16:03:33

TS-011

Category: Signaling Pathways
CAS: 339071-18-0
Last Update: 2025-10-14 16:03:33

SCH 530348 sulfate

Category: Signaling Pathways
CAS: 705260-08-8
Last Update: 2025-10-14 16:03:33

BAG 956

Category: Signaling Pathways
CAS: 853910-02-8
Last Update: 2025-10-14 16:03:33

YM758

Category: Signaling Pathways
CAS: 312752-85-5
Last Update: 2025-10-14 16:03:33

Thalidomide-PEG4-NH2

Category: Signaling Pathways
CAS: 2387510-82-7
Last Update: 2025-10-14 16:03:33


Supplier Name	MedChemExpress (MCE)
Contact	sales
Tel	609-228-6898
Mobile	609-228-6898
QQ
Email	sales@medchemexpress.com; tech@medchemexpress.com
Website	http://www.medchemexpress.com/
Wechat

Request for quotation

Supplier Contact